419 related articles for article (PubMed ID: 35121624)
1. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
[TBL] [Abstract][Full Text] [Related]
2. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
3. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
4. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A; Garralda E; Altintas I; Gieseke F; Geva R; Ben-Ami E; Maurice-Dror C; Calvo E; LoRusso PM; Alonso G; Rodriguez-Ruiz ME; Schoedel KB; Blum JM; Sänger B; Salcedo TW; Burm SM; Stanganello E; Verzijl D; Vascotto F; Sette A; Quinkhardt J; Plantinga TS; Toker A; van den Brink EN; Fereshteh M; Diken M; Satijn D; Kreiter S; Breij ECW; Bajaj G; Lagkadinou E; Sasser K; Türeci Ö; Forssmann U; Ahmadi T; Şahin U; Jure-Kunkel M; Melero I
Cancer Discov; 2022 May; 12(5):1248-1265. PubMed ID: 35176764
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
Hinner MJ; Aiba RSB; Jaquin TJ; Berger S; Dürr MC; Schlosser C; Allersdorfer A; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Matis L; Olwill SA
Clin Cancer Res; 2019 Oct; 25(19):5878-5889. PubMed ID: 31138587
[TBL] [Abstract][Full Text] [Related]
7. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
8. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
[TBL] [Abstract][Full Text] [Related]
9. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
[TBL] [Abstract][Full Text] [Related]
10. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.
Warmuth S; Gunde T; Snell D; Brock M; Weinert C; Simonin A; Hess C; Tietz J; Johansson M; Spiga FM; Heiz R; Flückiger N; Wagen S; Zeberer J; Diem D; Mahler D; Wickihalder B; Muntwiler S; Chatterjee B; Küttner B; Bommer B; Yaman Y; Lichtlen P; Urech D
Oncoimmunology; 2021; 10(1):2004661. PubMed ID: 35844969
[TBL] [Abstract][Full Text] [Related]
11. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
12. Batf3
Ziblat A; Horton BL; Higgs EF; Hatogai K; Martinez A; Shapiro JW; Kim DEC; Zha Y; Sweis RF; Gajewski TF
Cell Rep; 2024 May; 43(5):114141. PubMed ID: 38656869
[TBL] [Abstract][Full Text] [Related]
13. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
14. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y
Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096
[TBL] [Abstract][Full Text] [Related]
15. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.
Vezys V; Penaloza-MacMaster P; Barber DL; Ha SJ; Konieczny B; Freeman GJ; Mittler RS; Ahmed R
J Immunol; 2011 Aug; 187(4):1634-42. PubMed ID: 21742975
[TBL] [Abstract][Full Text] [Related]
17. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
18. B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8
You G; Lee Y; Kang YW; Park HW; Park K; Kim H; Kim YM; Kim S; Kim JH; Moon D; Chung H; Son W; Jung UJ; Park E; Lee S; Son YG; Eom J; Won J; Park Y; Jung J; Lee SW
Sci Adv; 2021 Jan; 7(3):. PubMed ID: 33523913
[TBL] [Abstract][Full Text] [Related]
19. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
[TBL] [Abstract][Full Text] [Related]
20. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
